Hansoh Pharmaceutical Group Company Limited (3692.HK, "Hansoh Pharma"), a leading innovation-driven pharmaceutical company in China committed to improving human health through continuous innovation, with a focus on the treatment of major diseases including oncology, infectious diseases, central nervous system (CNS) disorders, metabolic diseases and autoimmune diseases, among others, and the Global Health Drug Discovery Institute ("GHDDI"), a not-for-profit, innovative drug R&D organization committed to building a world-leading platform for new drug R&D and translational innovation to address major disease challenges in the global health sector, recently announced that they have entered into an exclusive licensing and co-development agreement (the "Licensing Agreement") for the global development, production and commercialization of the anti-novel coronavirus new drug candidate GDI-4405 series.
The candidate GDI-4405 series is an oral small molecule 3-CL (3C-like) protease inhibitor, which exhibits high potent antiviral activity on delta and omicron variants. Pursuant to the Licensing Agreement, Hansoh Pharma will be granted exclusive worldwide rights to develop, manufacture and commercialize the GDI-4405 series, and will pay a RMB 12 million upfront payment and potential payments upon reaching development, regulatory and sales-based commercial milestones of up to RMB 1,680 million, plus tiered royalties on future net sales.
"In recent years, the continuous mutation of the novel coronavirus has led to repeated outbreaks around the world, seriously threatening human life and health. Oral anti-novel coronavirus drugs can help patients further improve their defense and treatment solutions against the novel coronavirus." Ms. Sun Yuan, Executive Director of Hansoh Pharma, remarked, "We are very pleased to collaborate with GHDDI, which has the world's leading drug R&D platform, to develop an oral anti-novel coronavirus drug. The new drug candidate GDI-4405 series has excellent antiviral activity, and is expected to bring new treatments to more patients with the novel coronavirus and help Hansoh Pharma fully serve the Healthy China strategy and live up to its commitments as a pharmaceutical company."
"We are very pleased to enter into this strategic collaboration with Hansoh Pharma." Ding Sheng, Director of GHDDI, remarked, "With Hansoh Pharma's proven development and commercialization capabilities, we believe that we can accelerate the multiple studies and commercialization of this new drug candidate, enhance the clinical value and accessibility of the innovative drug, and provide a more effective, convenient and accessible oral drug for novel coronavirus treatments worldwide, so as to serve the major needs in China, address global health challenges, and create a community with a shared future for mankind."
About Hansoh Pharma
Founded in 1995, Hansoh Pharmaceutical Group Company Limited, the main business entity of Hansoh Pharma, is a leading innovation-driven pharmaceutical company in China. Adhering to the corporate mission to create excellence in pharmaceuticals and enhance innovation in China, Hansoh Pharma focuses on the treatment of oncology, infection, CNS, metabolism and autoimmunity diseases, and is committed to improving human health through continuous innovation. Up to now, Hansoh Pharma has marketed six innovative drugs and formed a rich pipeline, ranked among the top 30 of China's Top 100 Companies in Pharmaceutical Industry and the top 3 of China's Best Industrial Enterprises in Pharmaceutical R&D Pipeline for consecutive years. It is a national key high-tech enterprise and national technology innovation demonstration enterprise. Hansoh Pharma went public on the Stock Exchange of Hong Kong Ltd. in June 2019 (SEHK: 3692).
About GHDDI
The Global Health Drug Discovery Institute (GHDDI) was co-founded in 2016 by the Bill & Melinda Gates Foundation, Tsinghua University and the Beijing Municipal Government. As China's first not-for-profit, innovative drug R&D organization founded through a Public-Private Partnership (PPP), GHDDI is committed to developing innovative drugs and new technologies to address major disease challenges in the global health sector. GHDDI focuses on translational research from the laboratory to the clinic, and its key research areas include antiviral research for the 2019 coronavirus disease (COVID-19) and disease research for tuberculosis, malaria, parasitic infections and environmental intestinal dysfunction.
For more information about GHDDI, please visit www.ghddi.org.
